Aclarion Inc. (NASDAQ: ACON, ACONW) announced it has established a second commercial agreement with Weill Cornell Medicine to use its Nociscan platform in a clinical trial.

The agreement brings Nociscan technology to Weill Cornell Medicine and Och Spine at NewYork-Presbyterian/Weill Cornell Medical Center through a trial led by neurosurgeon Roger Härtl. The study, titled "Bone Marrow Aspirate Concentrate Injection with MRI's - a Prospective Randomized Controlled Trial," operates under IRB Protocol No. 24-09027977.

The two-year prospective study will evaluate the long-term effects of lumbar microdiscectomy surgery with and without an intradiscal bone marrow aspirate concentrate injection on patient outcomes, intervertebral disc health, and pain biomarkers. The research aims to enhance understanding of degenerative disc disease causes and treatments.

"Our scientific interest focuses on clinical and basic science research surrounding innovative and less invasive surgical and biological treatment strategies for degenerative diseases of the spine," said Härtl, who serves as a paid consultant for Aclarion. "This trial strives to enhance our understanding of disc degeneration in patients, and illuminate chemical aspects of disc degeneration not available with traditional imaging."

This marks the second trial at Weill Cornell Medicine to incorporate Nociscan technology. The platform uses magnetic resonance spectroscopy data and algorithms to help physicians distinguish between painful and nonpainful discs in the lumbar spine.

The information is based on a company press release.